Quick Answer
Passage BIO, Inc. reported Cash and Equivalents of $46.30 million for fiscal year 2025.
Passage BIO, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $46.30M | +23.2% |
| 2024 | $37.57M | +73.1% |
| 2023 | $21.71M | -37.3% |
| 2022 | $34.60M | -73.2% |
| 2021 | $128.97M | -4.5% |
| 2020 | $135.00M | -15.0% |
| 2019 | $158.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $52.77M | +63.4% | -8.4% |
| June 30, 2025 | $57.63M | +132.6% | -9.0% |
| March 31, 2025 | $63.36M | +72.3% | +68.6% |
| December 31, 2024 | $37.57M | +73.1% | +16.4% |
| September 30, 2024 | $32.29M | -3.8% | +30.4% |
| June 30, 2024 | $24.77M | -18.2% | -32.6% |
| March 31, 2024 | $36.77M | +10.2% | +69.4% |
| December 31, 2023 | $21.71M | -37.3% | -35.3% |
- Passage BIO, Inc. showed an increase of +23.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Passage BIO, Inc.’s cash and equivalents has declined by 70.9% (from $158.87 million to $46.30 million).
- The most recent figure is from Passage BIO, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: